Boehringer Ingelheim Announces $650 Million Deal to Settle Pradaxa Litigation

EAST ST. LOUIS, Ill. — Boehringer Ingelheim has agreed to pay $650 million to settle approximately 4,000 state and federal lawsuits alleging injuries caused by its prescription blood thinner Pradaxa.

The company said in a statement released May 28 that it expects most — if not all — of the plaintiffs will accept terms of the master settlement agreement, which has not yet been filed in the federal Pradaxa MDL in U.S. District Court for the Southern District of Illinois (In re Pradaxa (Dabigatran Etexilate) Products Liability Litigation, MDL No. 2385 [S.D. Ill.])

According to Boehringer, the settlement allows the …